[Malignant nephroangiosclerosis. Development and treatment].
D000328:Adult; D000814:Aniline Compounds / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000150:complications; D003937:Diagnosis, Differential; D005260:Female; D005921:Glomerulonephritis / Q000175:diagnosis; D006801:Humans; D006974:Hypertension, Malignant / Q000150:complications / Q000175:diagnosis* / Q000401:mortality; D007093:Imidazoles / Q000627:therapeutic use; D007511:Ischemia; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D009400:Nephrosclerosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D011697:Purpura, Thrombotic Thrombocytopenic / Q000150:complications; D012110:Reserpine / Q000627:therapeutic use
D000814:Aniline Compounds; D000959:Antihypertensive Agents; D007093:Imidazoles; D012110:Reserpine
Néphroangiosclérose maligne. Evolution et traitement.